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Chagas’ disease, caused by Trypanosoma cruzi infection, is one of the main causes of death due to heart
failure in Latin American countries. Benznidazole, the chemotherapeutic agent most often used for the
treatment of chagasic patients, is highly toxic and has limited efficacy, especially in the chronic phase of the
disease. In the present study we used a mouse model of chronic Chagas’ disease to investigate the effects of
benznidazole treatment during the chronic phase on disease progression. The hearts of benznidazole-treated
mice had decreased parasitism and myocarditis compared to the hearts of untreated chagasic mice. Both
groups of Trypanosoma cruzi-infected mice had significant alterations in their electrocardiograms compared to
those of the healthy mice. However, untreated mice had significantly higher cardiac conduction disturbances
than benznidazole-treated mice, including intraventricular conduction disturbances, atrioventricular blocks,
and extrasystoles. The levels of antibodies against T. cruzi antigens (epimastigote extract, P2, and trans-
sialidase) as well as antibodies against peptides of the second extracellular loops of 1-adrenergic and
M2-muscarinic cardiac receptors were also lower in the sera from benznidazole-treated mice than in the sera
from untreated mice. These results demonstrate that treatment with benznidazole in the chronic phase of
infection prevents the development of severe chronic cardiomyopathy, despite the lack of complete parasite
eradication. In addition, our data highlight the role of parasite persistence in the development of chronic
Chagas’ disease and reinforce the importance of T. cruzi elimination in order to decrease or prevent the
development of severe chagasic cardiomyopathy.
Chagas’ disease, caused by the protozoan Trypanosoma
cruzi, is a serious health problem in Latin America, where it
affects 16 million to 18 million people (43). In the acute phase
of the disease in humans, clinical signs are usually mild, despite
high levels of parasitemia in blood, which is characteristic of
this phase of infection and which declines with the onset of
immunity (18). After this phase, individuals recover to an ap-
parently healthy status, but a mild focal myocarditis may per-
sist and may last for years without signs of cumulative damage
in the indeterminate phase of the disease (3). Many years after
the primary infection, about 30% of these individuals develop
the symptomatic chronic phase of Chagas’ disease. This phase
is characterized by the presence of myocarditis and/or patho-
logical disturbances in the peripheral nervous and gastrointes-
tinal systems (15, 37).
The most common chronic form of the disease is chagasic
cardiomyopathy, a fatal form for which no effective treatments
are available. It is characterized by focal or disseminated in-
flammatory infiltrates, myocytolysis, and myonecrosis and pro-
gressive deposition of fibrotic tissue (11, 29). The intensity of
the myocarditis varies considerably from light cardiac symp-
toms to intense chronic cardiomyopathy, leading to heart
failure and death (31). Patients with chronic chagasic cardio-
myopathy may have diverse arrhythmias that cause heart mal-
function. The most frequent alterations recorded are ventric-
ular premature beats, complete right bundle branch block, left
anterior fascicular block, and atrioventricular block (27).
The mechanisms responsible for the cardiomyopathy are not
clearly understood, but the presence of chronic myocardial
injury in the absence of parasitemia suggests the participation
of autoimmune processes (21, 26, 35). Many hypotheses have
been proposed to explain the cardiomyopathy of Chagas’ dis-
ease, and these proposed causes of cardiomyopathy may act
alone or in combination. They include the breakdown of the
tolerance to self-antigens induced by polyclonal activation of
the immune system by the parasite (33) or by T. cruzi-specific
immune responses cross-reactive to self-antigens through a
mechanism of molecular mimicry (13, 24), T. cruzi-specific
immune responses acting in the residual parasites during the
chronic phase of infection (34), and microvascular abnormal-
ities (30). Several T. cruzi antigens have epitopes similar to
those of mammalian cardiac antigens, such as cardiac myosin
and the second loop of the human 1-adrenergic receptor (16,
38). Antibodies from chronic chagasic patients induce 1-ad-
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renergic and M2-muscarinic effects on the myocardium, result-
ing in alterations of electrocardiographic (ECG) findings cor-
related to electrical abnormalities, as described in the
literature (12, 14). However, there is also evidence that para-
site persistence or reinfection influences the severity of the
disease (8, 41). This may be due to the direct participation of
anti-T. cruzi immune responses and/or by its influence on au-
toimmune responses (35).
The main drug available for the treatment for Chagas’ dis-
ease is benznidazole, whose action eliminates T. cruzi parasites.
This compound, however, has limited efficacy and a degree of
high toxicity. In humans, benznidazole treatment is effective at
parasite eradication mainly in the acute phase of infection but
not in the prevalent chronic stage of the disease (10). Several
studies have investigated the efficacy of benznidazole treat-
ment during chronic infection in mice. In those studies (1, 2, 9,
32, 39), the investigators focused on the analysis of parasite
eradication and confirmed in the mouse model that benznida-
zole treatment during the chronic phase does not completely
eliminate the parasite. The effects of benznidazole treatment
for experimental chronic chagasic myocarditis are controver-
sial. Segura et al. (32) did not observe a significant decrease in
myocarditis in mice treated with benznidazole during the
chronic phase of infection, whereas in the work by Andrade et
al. (1), when parasitological cure was achieved, benznidazole-
treated mice had a decreased incidence of myocarditis.
Given the lack of therapeutic options for Chagas’ disease,
the potential benefits of benznidazole treatment in the chronic
phase of the disease should be carefully examined. In the
present study we used a murine model of chronic chagasic
cardiomyopathy caused by a myotropic T. cruzi strain to re-
evaluate the beneficial effects of benznidazole treatment dur-
ing the chronic phase of Chagas’ disease. The goal of the
benznidazole treatment was to cause a decrease in the residual
parasite load present during the chronic phase of infection and
analyze its influence on the development of heart alterations
characteristic of this disease. The decrease in parasitism result-
ing from the benznidazole treatment were correlated to his-
topathological and ECG parameters, as well as to the levels of
antibodies specific for T. cruzi antigens and 1-adrenergic and
M2-muscarinic receptors, in order to determine if the treat-
ment results in decreased heart pathology even in absence of a
parasitological cure.
MATERIALS AND METHODS
Animals, infection, and chemotherapy. Two-month-old male BALB/c mice,
raised and maintained in the animal facilities at the Gonc¸alo Moniz Research
Center, Fundac¸a˜o Oswaldo Cruz, were used in the experiments and were pro-
vided with rodent diet and water ad libitum. Mice were infected by intraperito-
neal injection of 100 trypomastigote forms of the Colombian strain of T. cruzi
(17). Trypomastigotes were obtained by in vitro infection of LCC-MK2 cells.
Parasitemia was evaluated at different times after infection by counting the
number of trypomastigotes in peripheral blood aliquots placed between a glass
slide and a coverslip (6). Forty-five days after infection, a group of 10 mice was
treated by the oral route with 100 mg of benznidazole (Rochagan; Roche) per kg
of body weight daily for 1 week, followed by weekly administrations for an
additional 8 months. All animals were killed while they were under anesthesia
and were handled according to the guidelines of the National Institutes of Health
for the ethical use of laboratory animals.
ECG records. ECGs were performed with a Bio Amp device PowerLab System
(PowerLab 2/20; ADInstruments, Castle Hill, Australia), which recorded bipolar
lead I. All animals were anesthetized by intraperitoneal injection of xylazine at 10
mg/kg of body weight and ketamine at 100 mg/kg of body weight. ECG record-
ings were obtained after the induction of general anesthesia. All data were
acquired on a computer for further analysis by using Chart 5 for Windows
software (Power Lab; ADInstruments). Wave durations (in milliseconds) were
calculated automatically by the software after placement of the cursors. Mea-
surements are average values determined from 14 consecutive ECG records.
Records were filtered (1 to 100 Hz) through a band-pass filter to minimize
environmental signal disturbances. The sampling rate was 1 kHz. The ECG
analysis included the following measurements: heart rate, PR interval, P-wave
duration, QT interval, QTc, atrioventricular block, intraventricular block, and
other arrhythmias. The software used a derivative-based QRS detection algo-
rithm to calculate the heart rate by detecting the peaks of the R waves automat-
ically. As the T waves are normally not separated from the QRS complex in
rodent ECGs (5), we measured the QT interval instead of the QRS complex
duration. The QT interval was measured from the beginning of the QRS to the
end of the T wave. The definition of the end of the T wave was the point where
the signal returned to the isoelectric line (42). The QTc was calculated as the
ratio of the QT interval to the square root of the RR interval.
Histopathological analysis. The hearts of the benznidazole-treated mice and
untreated controls were removed and fixed in buffered 10% formalin. Sections of
paraffin-embedded tissue were stained by the standard hematoxylin-eosin and
Sirius red staining methods for evaluation of inflammation and fibrosis, respec-
tively, by optical microscopy. Images were digitalized with a color digital video
camera (CoolSnap, Montreal, Quebec, Canada) adapted to a BX41 microscope
(Olympus, Tokyo, Japan). The images were analyzed with the Image Pro pro-
gram (version 5.0; Media Cybernetics, San Diego, Calif.) to integrate the number
of inflammatory cells counted by the area. The cells in 10 fields per heart from
each mouse in each group were counted.
Immunofluorescence for parasite detection. Five-micrometer-thick frozen
heart sections were prepared in a cryostat in poly-L-lysine-coated slides and were
fixed with cold acetone. Sections were incubated with phosphate-buffered saline
(PBS)– 5% bovine serum albumin for 30 min, followed by overnight incubation
with anti-T. cruzi rat serum (1:400). After the sections were washed with PBS,
they were incubated for 1 h with fluorescein isothiocyanate-conjugated rabbit
anti-rat immunoglobulin G (1:100; Sigma) adsorbed with normal mouse serum.
The sections were washed three times, counterstained with Evans blue, and
mounted with Vectashield (Vector). Images were digitalized with a color digital
video camera (DP-70) adapted to an Olympus AX-70 microscope with a motor-
ized stage xyz (Media Cybernetics) and in a FV-500 confocal system with an IX
81 inverted microscope (Olympus). The images were analyzed by use of the
Image Pro program (version 5.0; Media Cybernetics) so that the parasite foci
could be counted and integrated by the area.
Antigen preparations. Epimastigotes of the Colombian strain of T. cruzi were
obtained from axenic cultures grown in liver infusion tryptose medium. The
parasites were washed three times in PBS at 4°C, resuspended in distilled water,
and submitted to five cycles of freezing and thawing. The extract was made
isotonic by addition of PBS concentrated 10-fold and was centrifuged at 30,000
 g for 30 min. The supernatant was aliquoted and stored at 70°C. Recombi-
nant P2 was kindly donated by Mariano Levin. Recombinant trans-sialidase (TS)
was produced and purified from Escherichia coli cells transformed with plasmid
pTS-cat7, as described previously (28). Peptides of the second extracellular loops
of 1-adrenergic (residues 197 to 222) and M2-muscarinic (residues 164 to 185)
cardiac receptors were synthesized in an automatic peptide synthesizer by the
9-fluorenylmethoxy carbonyl technique by using solid-phase automatic synthesis.
Their purities were checked by high-performance liquid chromatography after
cleavage and desalting on a P2 column.
Antibody detection. Sera from untreated, benznidazole-treated, and unin-
fected mice were tested for the presence of antibodies against T. cruzi antigen,
TS, P2, and the M2-muscarinic and 1-adrenergic cardiac receptors by enzyme-
linked immunosorbent assay. Microtiter plates (Maxisorb; Nunc) were coated
overnight at 4°C with T. cruzi antigen (3 g/ml), P2 (1.5 g/ml), TS (1 g/ml),
and the M2-muscarinic and 1-adrenergic cardiac receptor peptides (500 ng/ml)
in 50 l of carbonate-bicarbonate buffer (pH 9.6). The plates were washed three
times in washing buffer (0.05% Tween 20 in PBS) and blocked with PBS–5%
nonfat milk for 2 h at room temperature. The sera were diluted 1:100 (for P2),
1:800 (for T. cruzi antigen), 1:1,200 (for TS), and 1:25 (for the M2-muscarinic and
1-adrenergic cardiac receptor peptides) in PBS–5% nonfat milk and incubated
for 2 h at room temperature. After the plates were washed, 50 l of peroxidase-
conjugated anti-mouse polyvalent immunoglobulins (Sigma) diluted 1:1,000 was
dispensed into each well and the plate was incubated for 30 min at room
temperature. The plates were washed eight times in washing buffer, and the
reaction was developed with the 3,3,5,5-tetramethylbenzidine substrate (Sigma)
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and read at 450 nm in a Spectramax 190 microplate reader (Molecular Devices,
Sunnyvale, Calif.).
Statistical analyses. Histological and serological data were analyzed by Stu-
dent’s t test, one-way analysis of variance, and the Newman-Keuls multiple-
comparison test, as indicated in the text, with Prism Software (version 3.0;
GraphPad Software, San Diego, Calif.). Statistical analyses of the cardiac pa-
rameters were performed with SPSS software (version 9.0; SPSS Inc., Chicago,
Ill.). The values for all continuous variables are presented as means  standard
errors. To test if the variables were normally distributed, we performed the
Kolmogorov-Smirnov test. Nonparametric tests (the Kruskall-Wallis and/or the
Mann-Whitney test) were used because the variables were not normally distrib-
uted by two-tailed hypothesis testing. Differences were considered significant if P
was equal to or less than 0.05.
RESULTS
Decreased parasitism and myocarditis in benznidazole-
treated mice. In order to investigate the effects of benznidazole
treatment in the chronic phase of T. cruzi infection, BALB/c
mice were treated with benznidazole for 8 months after the
acute phase of infection (Fig. 1). The hearts of mice in both the
untreated and the benznidazole-treated groups had detectable
parasite foci 10 months after infection (Fig. 2A and B). How-
FIG. 1. Parasitemia during the acute phase of infection with the
Colombian strain of T. cruzi in BALB/c mice. BALB/c mice were
infected with 100 trypomastigotes of the Colombian strain of T. cruzi.
Parasitemia was determined at different times after infection. Values
represent the medians for five mice. The arrow indicates the beginning
of benznidazole administration.
FIG. 2. Parasitism and histopathological analyses of heart sections of T. cruzi-infected mice. Heart sections of untreated (A and C) or
benznidazole-treated (B and D) T. cruzi-infected mice were analyzed for the presence of parasite foci by confocal microscopy (A and B;
magnification, 60) or inflammation by staining with hematoxylin-eosin (C and D; magnification, 40).
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ever, the number of parasite foci was threefold higher (P 
0.01) in the hearts of untreated mice than in those of benznida-
zole-treated mice (Fig. 3A). Histopathological analysis of heart
sections also demonstrated a twofold reduction (P  0.02) in
the numbers of inflammatory cells in benznidazole-treated
mice (Fig. 3B). No significant differences were observed (P 	
0.05) when the fibrotic areas of the hearts from untreated and
benznidazole-treated mice were compared (Fig. 3C).
Benznidazole treatment prevents the development of ECG
alterations in chronic Chagas’ disease. To investigate whether
benznidazole treatment in the chronic phase of infection ame-
liorates the cardiac function, ECG analysis was performed 10
months after infection. Both groups of T. cruzi-infected mice
had significant alterations (P  0.05) in various ECG param-
eters compared to those for the healthy mice, such as an
increased intrinsicoid deflection and an increased QT interval
(Table 1 and Fig. 4). Alterations in these parameters indicate
a delay in the conduction of the electric impulse and an in-
crease in the duration of the ventricular action potential. More
importantly, the ECGs of all untreated T. cruzi-infected ani-
mals showed severe cardiac conduction disturbances, such as
intraventricular conduction disturbances, atrioventricular
blocks, and extrasystoles (Table 1 and Fig. 4A). In contrast,
only 20% of the benznidazole-treated mice had cardiac con-
duction disturbances (intermittent intraventricular conduction
disturbances), while the remaining animals did not have any
conduction disturbances (Fig. 4B). Intermittent conduction
disturbances are clinically relevant but are much less severe
than the permanent intraventricular conduction disturbances
observed in the untreated infected animals. The heart rates of
the healthy mice were lower than those of the untreated and
benznidazole-treated mice, but the differences between the
healthy and chagasic mice were not statistically significant (Ta-
ble 1).
Decreased anti -T. cruzi antibody levels after benznidazole
treatment. The levels of antibodies against different T. cruzi
antigens were investigated. Sera from benznidazole-treated
mice had decreased levels of antibodies against T. cruzi extract
(P  0.001) compared to those in the sera of untreated T.
cruzi-infected mice (Fig. 5A). The levels of antibodies against
TS, an immunodominant T. cruzi antigen, were also signifi-
cantly lower (P 0.01) in benznidazole-treated mice (Fig. 5B).
Benznidazole-treated mice also had lower levels of antibodies
against P2 (P  0.01), a member of the acidic ribosomal
protein family from the protozoan parasite T. cruzi with struc-
tural similarities with cardiac receptors (Fig. 5C). The levels of
antibodies against peptides from the second extracellular loops
of the 1-adrenergic and the M2-muscarinic receptors were
also decreased in benznidazole-treated mice compared to the
levels in untreated T. cruzi-infected mice (Fig. 5D and E).
DISCUSSION
Parasite persistence occurs in most individuals infected with
T. cruzi. This can be demonstrated by diagnostic techniques
and can be illustrated by the recrudescence of the infection in
many patients with heart failure due to Chagas’ disease who
FIG. 3. Decreased parasitism and inflammation in the hearts of
benznidazole-treated mice determined by quantification of parasite
foci (A), inflammatory cells (B), and fibrosis (C) in heart sections of T.
cruzi-infected BALB/c mice untreated (I) or treated with benznidazole
(I  B). Values represent the means  standard deviations for 5 mice
per group (A) and 8 to 10 mice per group (B and C). , P  0.05
compared to the results for the untreated infected group by Student’s
t test.
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FIG. 4. ECG recordings from BALB/c mice. ECGs of untreated (A) and benznidazole-treated (B) T. cruzi-infected mice were recorded 10
months after infection. (C) ECG for a healthy BALB/c mouse. , P wave; 
, QRS complex; , second-degree atrioventricular block.
TABLE 1. Electrocardiographic parameters measured in the experimental groupsa
Experimental group
(no. of mice)
Heart rate
(no. of beats/
min)
PR interval
(ms)
P-wave
duration
(ms)
PR segment
(ms)
Intrinsicoid
deflection
(ms)
QT interval
(ms) QT
Cardiac conduction
disturbances (no. of
mice)
Infected (8) 270.3  30.3 39  2.6 18.5  2.4 21.9  1.4 16.1  2.9 41  2.5 2.9  0.2 IVCD (5), AVB (2),
ES (1)
Infected and treated
with benznidazole
(10)
256.7  15.7 35.5  2.1b 21.6  0.9 13.2  1.4b 15.8  1.7 43.5  2.8 2.6  0.2 IT-IVCD (2)
Healthy (18) 215.3  18.5 36.5  1.2 19.7  0.7 16.9  0.8c 9  0.7c 32.2  1.4c 1.9  0.9c IT-IVCD (1), ASI (1)
a Values represent the means  standard errors of the means for individual mice. IVCD, intraventricular conduction disturbance; AVB, atrioventricular block; ES,
extrasystole; IT-IVCD, intermittent intraventricular conduction disturbance; ASI, acute subendocardial ischemia.
b P  0.05 compared to the results for untreated infected mice.
c P  0.05 compared to the results for the T. cruzi-infected groups.
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undergo cardiac transplantation. When these patients are im-
munosuppressed, myocarditis usually develops in the trans-
planted heart and T. cruzi parasites are detected in the blood
and tissues (22, 36). Benznidazole is the main drug used for the
treatment of T. cruzi infection. However, although it is effective
when it is administered during the acute phase of the infection,
treatment with benznidazole is not believed to be able to elim-
inate the parasite during the chronic phase of infection (10). It
FIG. 5. Decreased levels of antibodies in sera from benznidazole-
treated mice. Sera of untreated (I) or benznidazole-treated (I  B) T.
cruzi-infected and health (N) BALB/c mice were tested by enzyme-
linked immunosorbent assay in order to determine the levels of anti-
bodies against T. cruzi antigen (A), TS (B), P2 (C), the second extra-
cellular loop of the human M2-muscarinic cardiac receptor (D), and
the second extracellular loop of the human 1-adrenergic cardiac re-
ceptor (E). The data represent the means  standard deviations for 5
to 10 mice for each group. , P  0.05 compared to the results for the
untreated infected group by one-way analysis of variance followed by
Newman-Keuls multiple-comparison test. O.D., optical density.
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has been proposed that latent forms of the T. cruzi parasite
present in tissues during the chronic phase of infection are not
eliminated by the chemotherapy (7).
In this report we demonstrated with a mouse model of in-
fection that although parasite eradication could not be
achieved with benznidazole treatment in the chronic phase, a
decrease in the parasite load could be observed. More impor-
tantly, we demonstrated for the first time that benznidazole
treatment caused a decrease in cardiac dysfunction (ECG al-
terations) and myocarditis, indicating that parasite persistence
plays an important role in the pathogenesis of chronic chagasic
cardiomyopathy. The observations of Bustamante and cowork-
ers (8) that reexposure to parasites through repeated infections
aggravates heart dysfunction corroborates this idea.
The beneficial effects of benznidazole treatment were
achieved by using a prolonged administration of a low dose in
mice infected with the Colombian strain of T. cruzi, a chemo-
therapy-resistant strain (1, 40). Thus, it is likely that benznida-
zole treatment is even more effective against chronic infections
caused by benznidazole-sensitive T. cruzi strains. In addition,
due to the high degree of toxicity of benznidazole, a low-dose
treatment similar to the one used in this work may be more
tolerable for humans.
Our results demonstrate that the sera of benznidazole-
treated mice had lower levels of antibodies specific to T. cruzi
antigens (trypomastigote extract, TS, and P2) than the sera of
the untreated group. It is possible that the higher antibody
levels participate in the increased severity of heart dysfunction
in untreated mice, as antibodies against T. cruzi antigens may
exert effects on cross-reactive epitopes on cardiac receptors
and modulate the function of the heart. In fact, it was observed
that sera from untreated mice had higher titers of antibodies
that recognized peptides from the second extracellular loop of
1-adrenergic and M2-muscarinic cardiac receptors. Sera from
chronic chagasic patients with severe cardiac arrhythmias in-
duced conduction disturbances, such as bradycardia and atrio-
ventricular conduction blockade, in isolated rabbit hearts per-
fused by the Langendorff technique. The effects of these sera
and immunoglobulin G fractions were abolished by atropine,
suggesting an involvement of the M2-muscarinic receptor (14).
By using an experimental model, it was demonstrated that
antibodies of chronic chagasic patients bind to the M2-musca-
rinic cardiac receptor in a noncompetitive manner and are able
to activate the receptor in an agonist-like form inducing L-type
Ca2 current inhibition (20). These results could well be cor-
related with clinical reports, since inhibition of this current
provokes atrioventricular blockade.
TS is an enzyme abundant on the T. cruzi parasite surface and
an immunodominant antigen recognized by sera from patients
with Chagas’ disease. In the present study we also observed that
benznidazole treatment decreased the levels of antibodies against
TS. This finding is reinforced by a recent study (25) that demon-
strated that benznidazole treatment of Chagas’ disease patients
induces a decrease in the reactivity of serum against recombinant
TS that correlates with parasite elimination.
The higher incidence of severe cardiac abnormalities in un-
treated mice was striking. All animals from this group had distur-
bances in heart electrogenesis. The alterations, intraventricular
conduction disturbances, atrioventricular blocks, and extrasysto-
les, are characteristic of chronic chagasic cardiomyopathy. As
mentioned above, the lower antibody levels in benznidazole-
treated mice may account for the better performance in cardiac
function in these animals. These data are in accordance with
those from previous reports which demonstrated that mice im-
munized with recombinant T. cruzi ribosomal P2 protein, which
reproduced the typical anti-P profile characteristic of chronic in-
fections, had ECG alterations without cardiac inflammatory le-
sions (4). Thus, in untreated mice, the higher levels of antibodies
and heart inflammation could explain the finding of cardiac con-
duction disturbances in the animals in this group, whereas in
benznidazole-treated mice these aggressive factors were de-
creased, resulting in better heart performance.
Chronic chagasic cardiomyopathy is a dilated cardiomiopa-
thy accompanied by acute and chronic inflammation, fibrosis,
and vasculitis. The mechanism by which this persistent inflam-
matory reaction occurs is not clearly known and occurs in only
about 25% of T. cruzi-infected individuals. Several reports
have recently demonstrated a role of autoimmune responses in
experimental models of chronic chagasic myocarditis (19, 23,
26). However, although the intensities of tissue parasitism and
inflammation do not have a direct correlation, parasite persis-
tence is probably required for disease development and main-
tenance (35). In this study, we observed a correlation between
decreased inflammation and parasitism in the myocardiums of
benznidazole-treated mice, which reinforces the importance of
residual parasitism in the development of chronic chagasic
myocarditis. As shown in a previous study (35), the profile of
the host’s immune response during T. cruzi infection is also
important in the development of the disease.
In conclusion, our results demonstrate the importance of
benznidazole treatment in chronic chagasic patients in order to
decrease or retard the development of chagasic cardiopathy,
even though complete parasite eradication is not achieved. In
addition, it reinforces the need for the discovery of new anti-T.
cruzi drugs with higher degrees of efficacy against the chronic
infection and fewer collateral effects. This will allow the more
efficient elimination of the parasite from T. cruzi-infected in-
dividuals and proper treatment of those patients who cannot
be treated with benznidazole due to its high degree of toxicity.
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